A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma

Table 1 Relationship between CREB5 mRNA level and clinicopathologic features (N = 72)

Characteristics	No. of patients		CREB5 2^-△△Ct Mean ± SEM	Non-parametric test value	P value
Characteristics	No.	%	CREB5 2^-△△Ct Mean ± SEM	Non-parametric test value	P value
Age (years)
≥60	34	47.22%	2.18 ± 0.25	Z = −0.073	0.942
<60	38	52.78%	2.16 ± 0.24
Gender
Male	41	56.94%	2.19 ± 0.23	Z = −0.034	0.973
Female	31	43.06%	2.15 ± 0.27
Smoking history
Nonsmoker	51	70.83%	2.27 ± 0.21	Z = −0.836	0.403
Smoker	21	29.17%	1.93 ± 0.28
Alcohol history
Nondrinker	47	65.28%	2.05 ± 0.18	Z = −0.396	0.692
Drinker	25	34.72%	2.40 ± 0.36
Tumor size (cm)
≥4	26	36.11%	2.75 ± 0.33	Z = −2.375	0.018
<4	46	63.89%	1.84 ± 0.18
Lymph node metastasis
pN1 to pN2	42	58.33%	1.93 ± 0.19	Z = −1.405	0.160
pN0	30	41.67%	2.51 ± 0.31
TNM stage
I	18	25.00%	2.40 ± 0.29	H = 11.917	0.008
II	17	23.61%	1.36 ± 0.22
III	19	26.39%	2.85 ± 0.35
IV	18	25.00%	1.99 ± 0.39
Pathological differentiation
Well	32	44.44%	2.19 ± 0.27	Z = −0.136	0.892
Moderately/poorly	40	55.56%	2.15 ± 0.22
Efficacy of TPF regimen
Non-CR	32	44.44%	1.29 ± 0.18	Z = −4.976	0.000
CR	40	55.56%	2.88 ± 0.22
Recurrence
Yes	56	77.78%	2.27 ± 0.20	Z = −0.935	0.350
No	16	22.22%	1.82 ± 0.32

Abbreviations: CREB5 cAMP response element-binding 5, SEM standard error of mean, CR cisplatin resistance, pN pathological lymph node status, TNM stage tumor-lymph node-metastasis stage; 2^-△△Ct indicates the difference in the cycle number at which a sample’s fluorescent signal passes a given threshold above baseline (Ct) derived from a specific gene compared with that of GAPDH in tumor tissues

ISSN: 1741-7015